BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Purpose: BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAFV600E mutation in their tumors. However, the development of resistance to BRAFi and MEKi remains a difficult clinical challenge with limited therapeutic options available to these patients. In this study, we investigated the mechanism and potential therapeutic utility of combination BRAFi and adoptive T-cell therapy (ACT) in melanoma resistant to BRAFi. Experimental Design: Investigations were performed in vitro and in vivo with various human melanoma cell lines sensitive and resistant to BRAFi as well as patient-derived xenografts (PDX) derived from patients. In addition, samples were evaluated from patients on a clinical trial of BRAFi in combination with ACT. Results: Herein we report that in human melanoma cell lines, senstitive and resistant to BRAFi and in PDX from patients who progressed on BRAFi and MEKi therapy, BRAFi caused transient upregulation of mannose-6-phosphate receptor (M6PR). This sensitized tumor cells to CTLs via uptake of granzyme B, a main component of the cytotoxic activity of CTLs. Treatment of mice bearing resistant tumors with BRAFi enhanced the antitumor effect of patients' TILs. A pilot clinical trial of 16 patients with metastatic melanoma who were treated with the BRAFi vemurafenib followed by therapy with TILs demonstrated a significant increase of M6PR expression on tumors during vemurafenib treatment. Conclusions: BRAF-targeted therapy sensitized resistant melanoma cells to CTLs, which opens new therapeutic opportunities for the treatment of patients with BRAF-resistant disease. See related commentary by Goff and Rosenberg, p. 2682

[1]  C. Yee.  Adoptive T cell therapy: points to consider. , 2018, Current opinion in immunology.

[2]  Yiling Lu,et al.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. , 2017, Cell reports.

[3]  A. Hauschild,et al.  Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. , 2017, European journal of cancer.

[4]  J. Schachter,et al.  Adoptive T cell therapy: An overview of obstacles and opportunities , 2017, Cancer.

[5]  J. Utikal,et al.  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Schachter,et al.  Adoptive Cell Therapy for Metastatic Melanoma. , 2017, Cancer journal.

[7]  D. Schadendorf,et al.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.

[8]  Shari Pilon-Thomas,et al.  Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors , 2016, Journal of Immunotherapy for Cancer.

[9]  S. Rosenberg,et al.  A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma , 2016, Clinical Cancer Research.

[10]  P. Gimotty,et al.  PIM kinases as therapeutic targets against advanced melanoma , 2016, Oncotarget.

[11]  Mark S. Cohen,et al.  The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma , 2016, Expert opinion on drug discovery.

[12]  A. Ribas,et al.  Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy , 2016, Therapeutic advances in medical oncology.

[13]  T. Graeber,et al.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. , 2013, The Journal of clinical investigation.

[14]  D. Gabrilovich,et al.  Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice , 2014, Cancer Immunology, Immunotherapy.

[15]  A. Aplin,et al.  Resistance to RAF inhibitors revisited , 2013, The Journal of investigative dermatology.

[16]  E. Hehenberger,et al.  The mannose 6-phosphate-binding sites of M6P/IGF2R determine its capacity to suppress matrix invasion by squamous cell carcinoma cells , 2013, The Biochemical journal.

[17]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[18]  S. Altiok,et al.  Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. , 2012, Cancer research.

[19]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[20]  V. Sondak,et al.  Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.

[21]  T. Graeber,et al.  BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. , 2012, Cancer research.

[22]  Alessandro Testori,et al.  The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.

[23]  Ruchir R. Shah,et al.  Abstract 3928: Inhibition of the ubiquitin proteasome system differentially regulates glucocorticoid receptor-mediated transcriptional processes , 2012 .

[24]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[25]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[26]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[27]  V. Sondak,et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.

[28]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[29]  B. Comin-Anduix,et al.  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.

[30]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[31]  S. Altiok,et al.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.

[32]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[33]  G. Korbutt,et al.  Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis , 2000, Cell.